<DOC>
	<DOCNO>NCT01832454</DOCNO>
	<brief_summary>This Study Single arm , Single Centre trail check safety efficacy bone marrow derive autologous mononuclear cell ( 100 million per dose ) trial conduct 36 month 100 patient ( 15 year age ) cerebral palsy India . Primary outcome measure improvement walk ability kinetic gait pattern .</brief_summary>
	<brief_title>Safety Efficacy Bone Marrow MNC Treatment Cerebral Palsy Subjects Below 15 Years</brief_title>
	<detailed_description>This Study Single arm , Single Centre trail check safety efficacy bone marrow derive autologous mononuclear cell ( 100 million per dose ) trial conduct 36 month 100 patient ( 15 year age ) cerebral palsy India . Primary outcome measure improvement walk ability kinetic gait pattern</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<criteria>Subject age 3 year 15 year diagnosis Cerebral Palsy . Regional Nerve damage show Magnetic Resonance Imaging ( MRI ) Able Comprehend give write informed consent form study willing come hospital follow visit per protocol requirement History meningitis , meningoencephalits , epilepsy life threaten allergic immune mediate reaction 2 Hemodynamically unstable patient history concurrent autoimmune disease acute episode Guillain barre syndrome peripheral Muscular dystropy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>cerebral palsy stem cell [ MNCS ]</keyword>
</DOC>